Skip to content

Dyne Therapeutics

US · DYN #2540 by market cap Listed 2020
15.50 -0.53 -3.31%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 4 in the most recent period (2026/Q3).
  • Total institutional ownership fell 12.6 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
103.70% -12.59pp
Institutions
301 +4
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund69.03%
VC/PE Fund17.70%
Hedge Fund12.02%
Public Company3.71%
Government Pension Fund0.64%
Individual/Insider0.27%
Private Company0.17%
Insurance Company0.16%
Endowment Fund0.13%

Top holders as of 2026-06-30

T. Rowe Price Group, Inc. 18.60% · 34.85M sh
BlackRock 7.72% · 14.47M sh
Janus Henderson Group plc 6.40% · 12.00M sh
FMR 5.95% · 11.15M sh
State Street Global Advisors 4.35% · 8.16M sh
Vanguard Capital Management, LLC 4.03% · 7.55M sh
Orbis Investment Management Limited 3.74% · 7.01M sh
Vanguard Portfolio Management, LLC 2.50% · 4.69M sh
TCG Crossover Management, LLC 2.46% · 4.62M sh
Geode Capital Management, LLC 2.35% · 4.40M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 15 buys · 35 sells

NameRoleStake
John Cox Chief Executive Officer 0.10%
Catherine Stehman-Breen Independent Director 0.05%
Oxana Beskrovnaya Chief Innovation Officer 0.04%
Johanna Friedl-Naderer Chief Commercial Officer 0.03%
Douglas Kerr Head of Research & Development and Chief Medical Officer 0.02%
Brian Posner Independent Director 0.01%
Richard Scalzo Former Senior VP and Head of Finance & Administration 0.01%
Erick Lucera CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer 0.01%
Atlas Venture Advisors, Inc. -- --
Edward Hurwitz Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-12 Douglas Kerr Head of Research & Development and Chief Medical Officer Intent to Sell (Form 144) -2,604 $16.82
2026-11-12 John Cox Chief Executive Officer Intent to Sell (Form 144) -5,513 $16.82
2026-10-19 Douglas Kerr Head of Research & Development and Chief Medical Officer Other Acquisition +8,000 --
2026-10-19 Douglas Kerr Head of Research & Development and Chief Medical Officer Other Derivative Acquisition +12,000 $16.27
2026-10-01 Brian Posner Independent Director Open Market Acquisition +2,500 $16.00
2026-09-07 Douglas Kerr Head of Research & Development and Chief Medical Officer Automatic Disposition -5,035 $18.88–24.35
2026-09-07 Douglas Kerr Head of Research & Development and Chief Medical Officer Intent to Sell (Form 144) -35 $18.89
2026-09-07 John Cox Chief Executive Officer Automatic Disposition -5,658 $18.88
2026-09-07 Johanna Friedl-Naderer Chief Commercial Officer Automatic Disposition -1,085 $18.88–24.35
2026-09-03 Douglas Kerr Head of Research & Development and Chief Medical Officer Intent to Sell (Form 144) -5,000 $24.35
2026-08-13 Atlas Venture Advisors, Inc. -- Automatic Disposition -2,586,928 $25.00–26.20
2026-08-12 Douglas Kerr Head of Research & Development and Chief Medical Officer Automatic Disposition -1,556 $26.28
2026-08-12 John Cox Chief Executive Officer Automatic Disposition -4,986 $26.28
2026-08-12 Erick Lucera CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer Automatic Disposition -1,797 $26.28
2026-08-12 Johanna Friedl-Naderer Chief Commercial Officer Automatic Disposition -226 $26.28
2026-07-26 Forbion Capital Partners B.V. -- Automatic Disposition -261,460 $25.50–26.04
2026-07-06 Atlas Venture Advisors, Inc. -- Automatic Disposition -772,451 $22.79–23.62
2026-07-06 Atlas Venture Advisors, Inc. -- Open Market Disposition -5,000 $23.61
2026-06-28 Atlas Venture Advisors, Inc. -- Automatic Disposition -504,695 $21.14–21.28
2026-06-24 Atlas Venture Advisors, Inc. -- Automatic Disposition -267,760 $21.02–21.13

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Dyne Therapeutics discussion 0 comments

Add a comment